Precision healthcare within the Asia-Pacific region has thrived over the past 12 months, with technology advancements like NGS and laboratory-developed tests, approvals such as a companion diagnostic test for lung cancer, and regulations across the region are continuing to evolve.

With such progression comes challenges like regulation, reimbursement, and market access – and so we’re delighted to introduce the first World Companion Diagnostics and Liquid Biopsy Summit APAC, coming to Singapore this November 13 and 14; a brand-new forum to unite precision medicine experts specializing in early biomarker research through to commercialization, and dive into these shared challenges.

See the conference agenda here: https://ter.li/dd9cv4 

Across two days, this conference offers unique opportunities to network with thought leaders, gain insights into the latest research and emerging trends, and exchange ideas with your peers to foster collaborations and drive innovation in healthcare.

Here’s what you can expect: 

• 19+ expert speakers from biopharma, academia and service providers including Johnson & Johnson, Sanofi, Takeda, CStone Pharma, Kyowa Kirin, Fudan University and more to create a comprehensive framework to successful drug-companion diagnostic co-development and robust biomarker testing to identify patients in need of precision therapies
• 19+ industry-led sessions and panel discussions, sharing valuable learnings and insights into the region’s biggest challenges of reimbursement, regulations, market access and more
• 6+ hours of dedicated networking time so you can connect with like-minded peers, enabling you to brainstorm how to overcome challenges in your role and create a path forward to ensure precision therapies become accessible to all patients  

 With complimentary* passes available for drug developers and researchers (*subject to terms and conditions), visit the website to register and view the terms: https://ter.li/1nrec7